<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163487</url>
  </required_header>
  <id_info>
    <org_study_id>ENT0031</org_study_id>
    <secondary_id>SU-05052010-5866</secondary_id>
    <secondary_id>18245</secondary_id>
    <nct_id>NCT01163487</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers</brief_title>
  <official_title>Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel T. Chang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the effect of the drug DCA (dichloroacetate) on&#xD;
      recurrent head and neck cancers. Part of this study will also use EF5 PET scan to study tumor&#xD;
      hypoxia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose of DCA in patients with recurrent head and neck cancer who have failed first-line therapy.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Head and Neck Cancers</condition>
  <arm_group>
    <arm_group_label>Dichloroacetate (DCA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg/kg/day, 37.5 mg/kg, or 50 mg/kg/day oral DCA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dichloroacetate</intervention_name>
    <description>25-50mg/kg per day; oral</description>
    <arm_group_label>Dichloroacetate (DCA)</arm_group_label>
    <other_name>DCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EF5</intervention_name>
    <description>21 mg/kg; IV</description>
    <arm_group_label>Dichloroacetate (DCA)</arm_group_label>
    <other_name>EF-5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed head and neck squamous cell carcinoma&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Patients must have unresectable disease in which there is no accepted potentially&#xD;
             curative treatment option&#xD;
&#xD;
          -  Patients must have acceptable organ and marrow function as defined below:&#xD;
&#xD;
          -  leukocytes &gt;3,000/uL&#xD;
&#xD;
          -  absolute neutrophil count &gt;1,500/uL&#xD;
&#xD;
          -  platelets &gt;90,000/uL&#xD;
&#xD;
          -  total bilirubin &lt;=1.5X normal institutional limits&#xD;
&#xD;
          -  AST(SGOT)/ALT(SGPT) &lt;=2.5 X normal institutional limits with the following exceptions:&#xD;
&#xD;
               1. Patients with documented tumors involving the liver who have Grade &lt;2 elevations&#xD;
                  in AST, ALT, and/or alkaline phosphatase are eligible if &lt;5X ULN.&#xD;
&#xD;
               2. Patients with documented tumors involving bone who have a Grade &lt;2 elevation in&#xD;
                  alkaline phosphatase are eligible if &lt;5X ULN.&#xD;
&#xD;
          -  creatinine &lt;=1.5X normal institutional limits OR creatinine clearance &gt;50 mL/min on&#xD;
             the basis of the Cockcroft-Gault glomerular filtration rate estimation&#xD;
&#xD;
          -  Patients must have non-cranial gross disease that is greater than 1 cm on CT scan&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Disease must be FDG-avid on PET scanning&#xD;
&#xD;
          -  Creatinine within normal institutional limits&#xD;
&#xD;
          -  Eastern Clinical Oncology Group performance status 0, 1 or 2 (Appendix 1)&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Both men and women and members of all races and ethnic groups are eligible for this&#xD;
             trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Administration of any systemic cytotoxic agents within the last 2 weeks of enrollment&#xD;
&#xD;
          -  Patients who are unwilling or unable to provide informed consent&#xD;
&#xD;
          -  Patients who have potentially curable disease&#xD;
&#xD;
          -  Participation in another concurrent treatment protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel T Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 6, 2010</study_first_submitted>
  <study_first_submitted_qc>July 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Daniel T. Chang</investigator_full_name>
    <investigator_title>Assistant Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

